human | Q5 |
P496 | ORCID iD | 0000-0002-2512-4531 |
P106 | occupation | researcher | Q1650915 |
Q50565053 | A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors. |
Q40690113 | A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer. |
Q42770955 | A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. |
Q59296874 | A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy |
Q36832238 | A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology. |
Q79329265 | A comparative study of volumetric analysis, histopathologic downstaging, and tumor regression grade in evaluating tumor response in locally advanced rectal cancer following preoperative chemoradiation |
Q50318351 | A locally advanced breast cancer with difficult differential diagnosis of carcinosarcoma and atypical medullary carcinoma, which had poor response to adriamycin- and taxane-based neoadjuvant chemotherapy: a case report. |
Q51356279 | A new prognostic index model using meta-analysis in early-stage epithelial ovarian cancer. |
Q38821431 | A novel TP53-KPNA3 translocation defines a de novo treatment-resistant clone in osteosarcoma |
Q46130279 | A phase 1, open label, dose escalation study to investigate the safety, tolerability, and pharmacokinetics of MG1102 (apolipoprotein(a) Kringle V) in patients with solid tumors. |
Q39827658 | A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer. |
Q84090042 | A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy |
Q82267815 | A phase II feasibility study of weekly paclitaxel in heavily pretreated advanced gastric cancer patients with poor performance status |
Q43281047 | A phase II study of a combined biweekly irinotecan and monthly cisplatin treatment for metastatic or recurrent gastric cancer. |
Q36612624 | A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens. |
Q34051972 | A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer |
Q84794314 | A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer |
Q43689423 | A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma. |
Q84372123 | A prognostic model to predict clinical outcome in gastric cancer patients with bone metastasis |
Q83979395 | A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy |
Q33399177 | A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. |
Q38731875 | ABCB1 2677G>T/A variant enhances chemosensitivity to anti-cancer agents acting on microtubule dynamics through LAMP1 inhibition. |
Q51666682 | ADAR-Mediated RNA Editing Predicts Progression and Prognosis of Gastric Cancer. |
Q40211834 | Activation of hypoxia-inducible factor-1alpha is necessary for lysophosphatidic acid-induced vascular endothelial growth factor expression. |
Q40113468 | An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients. |
Q33502227 | An attempt for combining microarray data sets by adjusting gene expressions |
Q34657590 | Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review |
Q87814813 | Angiogenic factor thymidine phosphorylase associates with angiogenesis and lymphangiogenesis in the intestinal-type gastric cancer |
Q39928916 | Angiogenic factor thymidine phosphorylase increases cancer cell invasion activity in patients with gastric adenocarcinoma. |
Q37650644 | Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients |
Q34444374 | Application of the Western-based adjuvant online model to Korean colon cancer patients; a single institution experience |
Q46324182 | Application of the adjuvant! Online model to Korean breast cancer patients: an assessment of prognostic accuracy and development of an alternative prognostic tool. |
Q47775732 | Assessment of Adrenal Function and Health-Related Quality of Life in Advanced Gastric Cancer Patients Who Received First-Line Chemotherapy |
Q82210847 | Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients |
Q81025165 | Attenuation of telomerase activity by hammerhead ribozyme targeting human telomerase RNA induces growth retardation and apoptosis in human breast tumor cells |
Q61800297 | Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial |
Q57463137 | BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression |
Q92817469 | Behaviors and Attitudes toward the Use of Complementary and Alternative Medicine among Korean Cancer Patients |
Q29620647 | Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study |
Q80730909 | Bilateral breast cancer: differential diagnosis using histological and biological parameters |
Q36067835 | Bone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patients |
Q33577959 | Brain metastases from colorectal carcinoma: prognostic factors and outcome. |
Q48208260 | Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer. |
Q41959108 | Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer |
Q57221322 | Caregiving burden and health-promoting behaviors among the family caregivers of cancer patients |
Q41186107 | Caregiving burden and the quality of life of family caregivers of cancer patients: the relationship and correlates. |
Q58542491 | Casein Kinase 2 Inhibitor, CX-4945, as a Potential Targeted Anticancer Agent in Gastric Cancer |
Q80320197 | Cetuximab rescue a patient with non-small cell lung cancer from rapid disease progression during chemotherapy |
Q41145098 | Changes in telomerase activity due to alternative splicing of human telomerase reverse transcriptase in colorectal cancer. |
Q38505143 | Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute. |
Q85823325 | Changing treatment patterns in elderly patients with resectable colon cancer |
Q35472842 | Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma treated with targeted therapies: results from the International mRCC Database Consortium |
Q42172414 | Characterizing the outcomes of metastatic papillary renal cell carcinoma |
Q84788817 | Chemokine growth-regulated oncogene 1 as a putative biomarker for gastric cancer progression |
Q100387543 | Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer |
Q39822963 | Circulating endothelial progenitor cells (EPC) for tumor vasculogenesis in gastric cancer patients. |
Q33619223 | Clinical features and treatment of collecting duct carcinoma of the kidney from the korean cancer study group genitourinary and gynecology cancer committee |
Q53517909 | Clinical features and treatment outcomes of advanced stage primary hepatic angiosarcoma. |
Q34354224 | Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea. |
Q37065537 | Clinical role of bone marrow angiogenesis in childhood acute lymphocytic leukemia |
Q37376890 | Clinical value of ezrin expression in primary osteosarcoma. |
Q34494770 | Clinicopathologic features of metachronous or synchronous gastric cancer patients with three or more primary sites. |
Q53250755 | Clinicopathological features and prognostic significance of HER2 expression in gastric cancer. |
Q104500409 | Comparative efficacy and tolerability of third-line treatments for advanced gastric cancer: A systematic review with Bayesian network meta-analysis |
Q34054383 | Comparison of Melanoma Subtypes among Korean Patients by Morphologic Features and Ultraviolet Exposure. |
Q33395803 | Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity. |
Q33888813 | Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer |
Q37536970 | Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy. |
Q37376227 | Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. |
Q38894275 | Controlling chemotherapy-induced nausea requires further improvement: symptom experience and risk factors among Korean patients. |
Q55400516 | CpG Island Methylator Phenotype and Methylation of Wnt Pathway Genes Together Predict Survival in Patients with Colorectal Cancer. |
Q53641389 | Cumulative Metformin Use and Its Impact on Survival in Gastric Cancer Patients After Gastrectomy. |
Q46678519 | Cyclic induction of senescence with intermittent AZT treatment accelerates both apoptosis and telomere loss. |
Q35188542 | Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. |
Q37123409 | DLEC1 is a functional 3p22.3 tumour suppressor silenced by promoter CpG methylation in colon and gastric cancers |
Q59115813 | Defining the target volume for post-operative radiotherapy after D2 dissection in gastric cancer by CT-based vessel-guided delineation |
Q33761681 | Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab |
Q92299126 | Development and evaluation of the Cancer Symptom Management System: Symptom Management Improves your LifE (SMILE)-a randomized controlled trial |
Q39203035 | Difference of interferon-α and interferon-β on melanoma growth and lymph node metastasis in mice. |
Q58600783 | Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma |
Q38332631 | Different role of functional domains of hTR in DNA binding to telomere and telomerase reconstruction. |
Q40320758 | Different subtypes of epithelioid sarcoma and their clinical implication: long-term multi-institutional experience with a rare sarcoma. |
Q33557905 | Differential Prognostic Implications of Gastric Signet Ring Cell Carcinoma: Stage Adjusted Analysis From a Single High-volume Center in Asia |
Q39401605 | Differential expression patterns of MMPs and their role in the invasion of epithelial premalignant tumors and invasive cutaneous squamous cell carcinoma. |
Q48689595 | Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma. |
Q54577559 | Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. |
Q33576276 | Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase II trials |
Q38189898 | Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. |
Q36348040 | EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI. |
Q64284309 | EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction |
Q45816663 | Economic and patient-reported outcomes of outpatient home-based versus inpatient hospital-based chemotherapy for patients with colorectal cancer. |
Q57211074 | Effect of being overweight on postoperative morbidity and long-term surgical outcomes in proximal gastric carcinoma |
Q37367458 | Efficacy and Toxicity of Mammalian Target Rapamycin Inhibitors in Patients with Metastatic Renal Cell Carcinoma with Renal Insufficiency: The Korean Cancer Study Group GU 14-08. |
Q33410008 | Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma. |
Q50090476 | Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG). |
Q82367592 | Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis |
Q34669352 | Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series |
Q50953072 | Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma. |
Q37315416 | Epigenomic profiling of primary gastric adenocarcinoma reveals super-enhancer heterogeneity |
Q37696106 | Epstein-Barr virus BARF1-induced NFκB/miR-146a/SMAD4 alterations in stomach cancer cells. |
Q53175509 | Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. |
Q83831946 | Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes |
Q34086969 | External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study |
Q59296888 | External validation of nomogram for the prediction of recurrence after curative resection in early gastric cancer |
Q37110135 | Fibroblast Growth Factor Receptor 1 Overexpression Is Associated with Poor Survival in Patients with Resected Muscle Invasive Urothelial Carcinoma |
Q27851960 | Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. |
Q33749070 | Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. |
Q37711680 | First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. |
Q34183978 | First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium |
Q36961529 | Follow-up after gastrectomy for cancer: the Charter Scaligero Consensus Conference. |
Q50050277 | Forty-nine gastric cancer cell lines with integrative genomic profiling for development of c-MET inhibitor. |
Q39698913 | Gaps exist between patients' experience and clinicians' awareness of symptoms after chemotherapy: CINV and accompanying symptoms. |
Q80376888 | Gastrointestinal stromal tumor of the rectum: an analysis of seven cases |
Q33365840 | Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. |
Q100519389 | Gene Expression Profiling Identifies Akt as a Target for Radiosensitization in Gastric Cancer Cells |
Q47844242 | Genetic Alterations among Korean Melanoma Patients Showing Tumor Heterogeneity: A Comparison between Primary Tumors and Corresponding Metastatic Lesions |
Q33296347 | Genome-wide genetic aberrations of thymoma using cDNA microarray based comparative genomic hybridization |
Q39612136 | Genome-wide molecular characterization of mucinous colorectal adenocarcinoma using cDNA microarray analysis. |
Q33781926 | Green tea consumption and stomach cancer risk: a meta-analysis. |
Q80555453 | Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines |
Q33990397 | High KLF4 level in normal tissue predicts poor survival in colorectal cancer patients |
Q38838849 | High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer |
Q38469106 | Identification of GABRA1 and LAMA2 as new DNA methylation markers in colorectal cancer |
Q34356765 | Identification of a radiosensitivity signature using integrative metaanalysis of published microarray data for NCI-60 cancer cells |
Q39729921 | Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells. |
Q38305699 | Identification of genes with correlated patterns of variations in DNA copy number and gene expression level in gastric cancer. |
Q53456797 | Identification of novel gastric cancer-associated CNVs by integrated analysis of microarray. |
Q33495849 | Identification of significant regional genetic variations using continuous CNV values in aCGH data. |
Q38197606 | Ifosfamide-induced Fanconi syndrome with diabetes insipidus. |
Q57068038 | Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial |
Q34007924 | Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy |
Q33343730 | Improving the prediction accuracy in classification using the combined data sets by ranks of gene expressions |
Q39937932 | In vitro pharmacogenomic database and chemosensitivity predictive genes in gastric cancer. |
Q34977196 | Incidence and Survival of Pediatric Soft Tissue Sarcomas: Comparison between Adults and Children |
Q79195955 | Increased expression of matrix metalloproteinase 9 correlates with poor prognostic variables in renal cell carcinoma |
Q38493648 | Increments of alpha-dystroglycan expression in liver metastasis correlate with poor survival in gastric cancer. |
Q44417564 | Infusional Fluorouracil, Etoposide, and Cisplatin (FEP) in Advanced and Relapsed Gastric Cancer |
Q35777894 | Institutional Board Review for Clinical Investigations on Inflammatory Bowel Diseases: A Single-Center Study |
Q39358547 | Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer |
Q59115799 | Integration of radiotherapy and chemotherapy for abdominal lymph node recurrence in gastric cancer |
Q46911437 | Intermediate dose 5-fluorouracil-induced encephalopathy. |
Q35154288 | Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy |
Q33795207 | Kaposi's Varicelliform-Like Eruption in a Patient Treated with Everolimus for Metastatic Renal Cell Carcinoma: Report of a Rare Case |
Q42876509 | Kidney Cancer Working Group report. |
Q47273213 | Lack of correlation between P-glycoprotein and chemotherapy resistance in nasal NK/T-cell lymphomas. |
Q52716996 | Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients. |
Q53525146 | Leiomyosarcoma: investigation of prognostic factors for risk-stratification model |
Q91249826 | Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale |
Q36292688 | Locoregional relapse after gastrectomy with D2 lymphadenectomy for gastric cancer. |
Q55608179 | Long-term survival after surgical resection for liver metastasis from gastric cancer: two case reports. |
Q38867037 | Low-concentration vemurafenib induces the proliferation and invasion of human HaCaT keratinocytes through mitogen-activated protein kinase pathway activation |
Q88780568 | MET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver metastasis |
Q90553378 | Marked Loss of Muscle, Visceral Fat, or Subcutaneous Fat After Gastrectomy Predicts Poor Survival in Advanced Gastric Cancer: Single-Center Study from the CLASSIC Trial |
Q36500021 | Mechanism of enhancement of radiation-induced cytotoxicity by sorafenib in colorectal cancer. |
Q38706540 | Modulation of HAT activity by the BRCA2 N372H variation is a novel mechanism of paclitaxel resistance in breast cancer cell lines. |
Q40942600 | Modulation of biological phenotypes for tumor growth and metastasis by target-specific biological inhibitors in gastric cancer. |
Q51911503 | Molecular basis of the differences between normal and tumor tissues of gastric cancer. |
Q53462601 | Molecular characterization of alternative SET-NUP214 fusion transcripts in a case of acute undifferentiated leukemia |
Q43614958 | Monthly 5-days 5-fluorouracil and low-dose leucovorin for adjuvant chemotherapy in colon cancer. |
Q80375798 | Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations |
Q45959241 | Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide. |
Q33375134 | Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. |
Q59330587 | Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy |
Q35152348 | Neoadjuvant chemoradiotherapy followed by D2 gastrectomy in locally advanced gastric cancer |
Q31116686 | Novel and simple transformation algorithm for combining microarray data sets. |
Q34193096 | Novel sunitinib strategy in metastatic renal cell carcinoma on hemodialysis: intermittent dose of sunitinib after hemodialysis |
Q33361612 | OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation. |
Q37357165 | Oncogenic pathway combinations predict clinical prognosis in gastric cancer. |
Q41755706 | Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. |
Q91347054 | Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma |
Q34138032 | Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. |
Q34428153 | Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy. |
Q38945020 | PINCH-2 presents functional copy number variation and suppresses migration of colon cancer cells by paracrine activity. |
Q36832212 | PTEN Methylation Dependent Sinonasal Mucosal Melanoma |
Q27853081 | PTEN deficiency as a predictive biomarker of resistance to HER2-targeted therapy in advanced gastric cancer. |
Q47838777 | PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer |
Q30417878 | Pain palliation in patients with bone metastases using magnetic resonance-guided focused ultrasound with conformal bone system: a preliminary report |
Q33410206 | Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients. |
Q36872919 | Pharmacogenomic assessment of outcomes of pemetrexed-treated patients with adenocarcinoma of the lung. |
Q33384540 | Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies. |
Q33503003 | Phase I clinical trial: pharmacokinetics of a novel anthracycline, DA-125 and metabolites. Single dose study |
Q57222268 | Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane |
Q41508355 | Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma |
Q46755330 | Phase II study of combination chemotherapy of 5-fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer. |
Q53247583 | Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)_KCSG GY10-10. |
Q54494004 | Phase II study of the safety and efficacy of temsirolimus in East Asian patients with advanced renal cell carcinoma. |
Q53458025 | Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer. |
Q33397403 | Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma. |
Q45093247 | Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. |
Q44130825 | Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma. |
Q39850176 | Phospholipase C delta 1 is a novel 3p22.3 tumor suppressor involved in cytoskeleton organization, with its epigenetic silencing correlated with high-stage gastric cancer. |
Q81800649 | Postoperative adjuvant chemotherapy of gastric cancer: scrutiny into the clinical evidence based on quality assessment of medical literature of randomized controlled trials |
Q38422833 | Prediction of high-risk patients by genome-wide copy number alterations from remaining cancer after neoadjuvant chemotherapy and surgery. |
Q34966145 | Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer |
Q83811955 | Prediction of recurrence of early gastric cancer after curative resection |
Q38410346 | Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer. |
Q43828828 | Prevalence and associated factors of psychological distress among Korean cancer patients. |
Q33587575 | Prevalence and prognostic implications of psychological distress in patients with gastric cancer |
Q41200095 | Prevalence of human papillomavirus infection and RAS mutation in sporadic keratoacanthoma. |
Q37316735 | Prognosis of pN3 stage gastric cancer. |
Q37015759 | Prognostic Model to Predict Survival Outcome for Curatively Resected Liposarcoma: A Multi-Institutional Experience |
Q50847454 | Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents. |
Q36230768 | Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib |
Q79456937 | Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: a 15-year experience at a single institute |
Q36072022 | Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. |
Q37269360 | Prognostic implications of PIK3CA amplification in curatively resected liposarcoma |
Q45308745 | Prognostic implications of anaplastic lymphoma kinase gene aberrations in rhabdomyosarcoma; an immunohistochemical and fluorescence in situ hybridisation study. |
Q49206365 | Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma. |
Q55026328 | Prognostic significance and frequency of EGFR expression and amplification in surgically resected advanced gastric cancer. |
Q38720296 | Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma |
Q38382303 | Promoter Methylation of PTEN Is a Significant Prognostic Factor in Melanoma Survival. |
Q39909656 | Promoter methylation of the Wnt/beta-catenin signaling antagonist Dkk-3 is associated with poor survival in gastric cancer |
Q48626617 | Proper timing of adjuvant chemotherapy affects survival in patients with stage 2 and 3 gastric cancer. |
Q49679541 | Rab25 augments cancer cell invasiveness through a β1 integrin/EGFR/VEGF-A/Snail signaling axis and expression of fascin. |
Q36065419 | Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer |
Q90473923 | Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept "3G" Trial |
Q37687784 | Receptor tyrosine kinase amplified gastric cancer: Clinicopathologic characteristics and proposed screening algorithm |
Q57299791 | Reconsideration of sample size and power calculation for overall survival in cancer clinical trials |
Q38803935 | Recursive partition analysis of peritoneal and systemic recurrence in patients with gastric cancer who underwent D2 gastrectomy: Implications for neoadjuvant therapy consideration |
Q33919180 | Regions of allelic imbalance in the distal portion of chromosome 12q in gastric cancer |
Q39668099 | Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial |
Q59352012 | Regulation of proliferation and invasion by the IGF signalling pathway in Epstein-Barr virus-positive gastric cancer |
Q36782534 | Regulation of the epithelial to mesenchymal transition and metastasis by Raf kinase inhibitory protein-dependent Notch1 activity. |
Q59794754 | Renal Cell Carcinoma Is Abrogated by p53 Stabilization through Transglutaminase 2 Inhibition |
Q36187013 | Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine. |
Q39861038 | Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee. |
Q37133691 | Rho GTPase RhoJ is Associated with Gastric Cancer Progression and Metastasis. |
Q40278455 | Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. |
Q86632070 | Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell |
Q46845089 | Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma. |
Q49348813 | S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial |
Q41907282 | S-1 monotherapy as a neoadjuvant treatment for locally advanced gastric cancer. |
Q33345613 | SNPAnalyzer 2.0: a web-based integrated workbench for linkage disequilibrium analysis and association analysis. |
Q54462541 | Safety of everolimus by treatment duration in patients with advanced renal cell cancer in an expanded access program. |
Q35233550 | Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer. |
Q36374816 | Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. |
Q93096106 | Significance of Metabolic Tumor Volume and Total Lesion Glycolysis Measured Using ¹⁸F-FDG PET/CT in Locally Advanced and Metastatic Gallbladder Carcinoma |
Q91014807 | Stability of symptom clusters and sentinel symptoms during the first two cycles of adjuvant chemotherapy |
Q33396613 | Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles. |
Q80785552 | Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases |
Q34896252 | Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. |
Q47597183 | Symptom clusters during palliative chemotherapy and their influence on functioning and quality of life. |
Q96827775 | Synergistic Antitumor Effects of Combined Treatment with HSP90 Inhibitor and PI3K/mTOR Dual Inhibitor in Cisplatin-Resistant Human Bladder Cancer Cells |
Q39439368 | Systematic analyses of genes associated with radiosensitizing effect by celecoxib, a specific cyclooxygenase-2 inhibitor. |
Q37596836 | Telomerase reverse transcriptase (TERT) promoter mutations in Korean melanoma patients. |
Q46427241 | Telomerase- and angiogenesis-related gene responses to irradiation in human umbilical vein endothelial cells. |
Q93183045 | Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma |
Q38832501 | The Benefit of Pro Re Nata Antiemetics Provided With Guideline-Consistent Antiemetics in Delayed Nausea Control. |
Q53607051 | The Clinicopathologic Features and Prognostic Impact of ALK Positivity in Patients with Resected Gastric Cancer. |
Q35561464 | The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study |
Q89285151 | The clinical implications of FDG-PET/CT differ according to histology in advanced gastric cancer |
Q38484252 | The clinical outcome of chemotherapy-induced amenorrhea in premenopausal young patients with breast cancer with long-term follow-up. |
Q79999473 | The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer |
Q34646724 | The effect of disintegrin-metalloproteinase ADAM9 in gastric cancer progression |
Q83201457 | The effect of spleen-preserving lymphadenectomy on surgical outcomes of locally advanced proximal gastric cancer |
Q36872857 | The impact of cigarette smoking on the frequency of and qualitative differences in KRAS mutations in Korean patients with lung adenocarcinoma |
Q34081616 | The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium |
Q40252205 | The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation. |
Q39067669 | The metalloprotease ADAMTS8 displays antitumor properties through antagonizing EGFR-MEK-ERK signaling and is silenced in carcinomas by CpG methylation |
Q53201331 | The prognostic value of volume-based parameters using 18F-FDG PET/CT in gastric cancer according to HER2 status. |
Q34612189 | The tumor suppressor Wnt inhibitory factor 1 is frequently methylated in nasopharyngeal and esophageal carcinomas. |
Q44537561 | Therapeutic strategies for well-differentiated papillary mesothelioma of the peritoneum. |
Q40419339 | Thymidine phosphorylase suppresses apoptosis induced by microtubule-interfering agents. |
Q104792688 | Transcriptome analysis of iBET-151, a BET inhibitor alone and in combination with paclitaxel in gastric cancer cells |
Q43958960 | Treatment of advanced gastric cancer by palliative gastrectomy, cytoreductive therapy and postoperative intraperitoneal chemotherapy. |
Q84871530 | Treatment of recurrent hepatocellular carcinoma after liver transplantation |
Q33385981 | Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea |
Q91695726 | Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function |
Q51195343 | Tumor perfusion-related parameter of diffusion-weighted magnetic resonance imaging: correlation with histological microvessel density. |
Q33566877 | Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer |
Q91567210 | Unmet needs in the physical and daily living domain mediates the influence of symptom experience on the quality of life of gastric cancer patients |
Q52965644 | Upregulated, 7q21-22 amplicon candidate gene SHFM1 confers oncogenic advantage by suppressing p53 function in gastric cancer. |
Q50670233 | Vascular soft-tissue sarcomas: a prognostic model from a retrospective single-center study. |
Q35877763 | Weekly gemcitabine and docetaxel in refractory soft tissue sarcoma: a retrospective analysis. |
Q53539819 | Whole genome analysis for liver metastasis gene signatures in colorectal cancer. |
Q53263421 | hTERT mediates norepinephrine-induced Slug expression and ovarian cancer aggressiveness. |
Q36482470 | p16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal Cancer |
Search more.